 |
|
Management of direct antiviral agent failures
María Buti, Rafael Esteban
Clin Mol Hepatol. 2016;22(4):432-438. Published online 2016 Dec 25 DOI: https://doi.org/10.3350/cmh.2016.0107
|
|
Citations to this article as recorded by
 Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs
Heba Omar, Mohammed Hamdy Abdel Maksoud, Ahmed A. Goma, Essam A. Hassan, Nancy Abdalla Atta, Mahmoud Khalil, Mohamed Soliman Hegazy, Samy Zaky, Gamal Esmat
Egyptian Liver Journal.2024;[Epub] CrossRef High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam
Thong Duy Vo, Van Thi Thu Bui, Huong Tu Lam, Quynh Thi Huong Bui
Pharmacology Research & Perspectives.2024;[Epub] CrossRef Is there a connection between neurocognitive profile in treatment naïve non-cirrhotic HCV patients and level of systemic inflammation?
Maja Ružić, Natalija Rajić, Željka Nikolašević, Aleksandar Spasić, Maria Pete, Vojislava Bugarski Ignjatović
Journal of NeuroVirology.2023; 29(6): 723. CrossRef Fatores associados à adesão ao tratamento da hepatite C: revisão integrativa
Layla Tatiane Côco, Giovanni Faria Silva, Fernando Gomes Romeiro, Ana Teresa de Abreu Ramos Cerqueira
Ciência & Saúde Coletiva.2022; 27(4): 1359. CrossRef Direct-acting antiviral retreatment patterns for hepatitis C
Shaquib Al Hasan, Daniel G Dauner, Abhijeet Rajpurohit, Joel F Farley
Journal of Managed Care & Specialty Pharmacy.2022; 28(10): 1100. CrossRef Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
Matthew J Akiyama, Lindsey Riback, Jacqueline D Reeves, Yolanda S Lie, Linda Agyemang, Brianna L Norton, Julia H Arnsten, Alain H Litwin
Open Forum Infectious Diseases.2021;[Epub] CrossRef Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
Edward Gane, Victor de Ledinghen, Douglas E. Dylla, Giuliano Rizzardini, Mitchell L. Shiffman, Stephen T. Barclay, Jose Luis Calleja, Zhenyi Xue, Margaret Burroughs, Julio A. Gutierrez
Journal of Viral Hepatitis.2021; 28(11): 1635. CrossRef Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors
Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk
Journal of Medical Virology.2021; 93(8): 4975. CrossRef Provider Perceptions of Hepatitis C Treatment Adherence and Initiation
Grace Zhang, Krupa Patel, Akshata Moghe, Andrea Reid, Marina Serper, Linda Calgaro, Sandra Gibson, Susan Zickmund, Obaid Shaikh, Shari Rogal
Digestive Diseases and Sciences.2020; 65(5): 1324. CrossRef Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins
Xinlei Li, Jinqian Li, Yetong Feng, Hua Cai, Yi-Ping Li, Tao Peng
Antiviral Research.2020; 177: 104734. CrossRef Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients
Hend Ibrahim Shousha, Yasmin Saad, Doa’a A. Saleh, Hosam Dabes, Magdy Alserafy, Yehia ElShazly, Mohamed Said
European Journal of Gastroenterology & Hepatology.2020; 32(8): 1017. CrossRef Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies
Monkez M. Yousif, Hussien Ahmed, Hany M. Elsadek, Ali M. shendi, Tamer M. Gouda, Islam A. Elsayed, Mohamed A. Gendia, Mahmoud M. Magdy, Nevin F. lbrahim, Ayman M. E. M. Sadek, Ayman M. Zaki, Hamdy Shafeik, Mahmoud H. Zahran
Journal of Viral Hepatitis.2020; 27(11): 1190. CrossRef Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes
Vanessa D. Costa, Carlos E. Brandão-Mello, Estevão P. Nunes, Pedro Guilherme Corôa dos Santos Silva, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello, Tatsuo Kanda
PLOS ONE.2019; 14(5): e0216327. CrossRef New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele', Tommaso Trenti
Journal of Clinical and Experimental Hepatology.2019; 9(4): 522. CrossRef Tolerability and effectiveness of generic direct‐acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients
Sameh A. Lashen, Mohammed M. Shamseya, Marwa A. Madkour, Galal A. Aboufarrag
Liver International.2019; 39(5): 835. CrossRef Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1
Vanessa Duarte Costa, Nathália Delvaux, Carlos Eduardo Brandão-Mello, Estevão Portela Nunes, Paulo Sérgio Fonseca de Sousa, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello
Clinics and Research in Hepatology and Gastroenterology.2019; 43(6): 700. CrossRef Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection
Yoshimi Shimizu, Kohei Yoneda, Yoshitaka Shirasago, Takeru Suzuki, Minoru Tada, Akiko Ishii-Watabe, Kazuo Sugiyama, Tetsuro Suzuki, Takaji Wakita, Kiyohito Yagi, Masuo Kondoh, Masayoshi Fukasawa
Biochemical and Biophysical Research Communications.2019; 514(3): 785. CrossRef Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
Vanessa D. Costa, Patricia Pellegrini, Vivian Rotman, Ana Maria Pittella, Estevão P. Nunes, Barbara V. Lago, Elisabeth Lampe, Francisco C. A. Mello
Viruses.2019; 11(11): 1004. CrossRef Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases
S. Miuma, H. Miyaaki, Y. Miyazoe, T. Suehiro, R. Sasaki, H. Shibata, N. Taura, K. Nakao
Transplantation Proceedings.2018; 50(1): 222. CrossRef Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed Zanaty, Mohamed Ramadan
Digestive Diseases and Sciences.2018; 63(5): 1341. CrossRef A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed I. Zanaty, Mohamed Ramadan
Journal of Hepatology.2018; 68(6): 1313. CrossRef The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study
Waleed Abdelfattah Ismail, Fady Maher Wadea
Drug Discoveries & Therapeutics.2018; 12(6): 368. CrossRef Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4+ T cells contributes to viral persistence in chronic hepatitis C
Ya Zhuo, Yi-Fu Zhang, Hong-Jie Wu, Lei Qin, Yan-Ping Wang, A-Min Liu, Xin-Hong Wang
Biomedicine & Pharmacotherapy.2017; 94: 386. CrossRef Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals
Jeong Han Kim
The Korean Journal of Gastroenterology.2017; 70(2): 111. CrossRef Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer
Hepatology Communications.2017; 1(8): 757. CrossRef Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
Mark W Sonderup, Mary Afihene, Reidwaan Ally, Betty Apica, Yaw Awuku, Lina Cunha, Geoffrey Dusheiko, Neliswa Gogela, Marie-Jeanne Lohouès-Kouacou, Phillip Lam, Olufunmilayo Lesi, Papa Saliou Mbaye, Emmanuel Musabeyezu, Betty Musau, Olesegun Ojo, John Rweg
The Lancet Gastroenterology & Hepatology.2017; 2(12): 910. CrossRef Retreatment Options Following HCV Direct-Acting Antiviral Failure
Autumn Zuckerman, Cody A. Chastain, Susanna Naggie
Current Treatment Options in Infectious Diseases.2017; 9(4): 389. CrossRef Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles
Longbo Hu, Jinqian Li, Hua Cai, Wenxia Yao, Jing Xiao, Yi-Ping Li, Xiu Qiu, Huimin Xia, Tao Peng
Antiviral Research.2017; 148: 5. CrossRef
|